| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Vasiliki Karalis, Franklin Caval-Holme, Helen S Bateu. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex. Nature communications. vol 13. issue 1. 2022-08-09. PMID:35945201. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder caused by mutations in the tsc1 or tsc2 genes, which encode proteins that negatively regulate mtor complex 1 (mtorc1) signaling. |
2022-08-09 |
2023-08-14 |
mouse |
| Paul A Roberson, Leonard S Jefferson, Scot R Kimbal. Convergence of Signaling Pathways in Mediating Actions of Leucine and IGF-1 on mTORC1 in L6 Myoblasts. American journal of physiology. Cell physiology. 2022-08-01. PMID:35912992. |
compared to leucine- and serum-deprived myoblasts, igf-1, but not leucine, promoted phosphorylation of protein kinase b (akt), tuberous sclerosis complex 2 (tsc2), and the autophosphorylation site on mtor (s2481) and also stimulated mtor kinase activity in mtor immunoprecipitated samples. |
2022-08-01 |
2023-08-14 |
Not clear |
| Yahong Zhao, Yunyun Liang, Zhixin Xu, Jina Liu, Xiaoyu Liu, Jinyu Ma, Cheng Sun, Yumin Yan. Exosomal miR-673-5p from fibroblasts promotes Schwann cell-mediated peripheral neuron myelination by targeting the TSC2/mTORC1/SREBP2 axis. The Journal of biological chemistry. 2022-02-13. PMID:35151688. |
subsequent functional studies revealed that mir-673-5p targets the regulator of mtor complex 1 (mtorc1) tsc2 in scs, leading to the activation of downstream signaling pathways including mtorc1 and srebp2. |
2022-02-13 |
2023-08-13 |
Not clear |
| Davide Bassetti, Heiko J Luhmann, Sergei Kirischu. Presynaptic GABA Pflugers Archiv : European journal of physiology. vol 473. issue 8. 2021-10-18. PMID:34279736. |
presynaptic gaba the tsc1 and tsc2 tumor suppressor genes control the activity of mechanistic target of rapamycin (mtor) pathway. |
2021-10-18 |
2023-08-13 |
Not clear |
| Till S Zimmer, Anatoly Korotkov, Susan Zwakenberg, Floor E Jansen, Fried J T Zwartkruis, Nicholas R Rensing, Michael Wong, Angelika Mühlebner, Erwin A van Vliet, Eleonora Aronica, James D Mill. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. Brain pathology (Zurich, Switzerland). vol 31. issue 5. 2021-10-13. PMID:33786950. |
tuberous sclerosis complex (tsc) is a congenital disorder characterized by cortical malformations and concomitant epilepsy caused by loss-of-function mutations in the mtor suppressors tsc1 or tsc2. |
2021-10-13 |
2023-08-13 |
Not clear |
| Jiao Jiao Zhang, Ya Qi Li, Yu Sha Wang, Liang Chen, Xian Zhong Wan. Estradiol ameliorates metformin-inhibited Sertoli cell proliferation via AMPK/TSC2/mTOR signaling pathway. Theriogenology. vol 175. 2021-10-12. PMID:34481229. |
in addition, scs transfected with the mir-1764 agomir led to an improvement of proliferation capacity through down-regulating ampkα2 level, which further decreased tsc2 expression and induced mtor activation. |
2021-10-12 |
2023-08-13 |
chicken |
| Anna Caliò, Matteo Brunelli, Diego Segala, Giuseppe Zamboni, Franco Bonetti, Maurizio Pea, Guido Martignon. Angiomyolipoma of the kidney: from simple hamartoma to complex tumour. Pathology. vol 53. issue 1. 2021-10-04. PMID:33131798. |
the activation of the mtor pathway due to genetic alterations of tuberous sclerosis complex in tsc1 or tsc2 genes in angiomyolipoma has also been reported as well as the subsequent therapeutic implications. |
2021-10-04 |
2023-08-13 |
Not clear |
| Christine Chin-Jung Hsieh, Yu-Chun Lo, Ssu-Ju Li, Ting-Chun Lin, Ching-Wen Chang, Ting-Chieh Chen, Shih-Hung Yang, Yi-Chao Lee, You-Yin Che. Detection of endophenotypes associated with neuropsychiatric deficiencies in a mouse model of tuberous sclerosis complex using diffusion tensor imaging. Brain pathology (Zurich, Switzerland). vol 31. issue 1. 2021-09-04. PMID:32530070. |
we previously used curcumin, a diet-derived mtor inhibitor, which possesses both anti-inflammatory and antiproliferative properties, to improve learning and memory deficits in tsc2 |
2021-09-04 |
2023-08-13 |
mouse |
| Tomas Petrasek, Iveta Vojtechova, Ondrej Klovrza, Klara Tuckova, Cestmir Vejmola, Jakub Rak, Anna Sulakova, Daniel Kaping, Nadine Bernhardt, Petrus J de Vries, Jakub Otahal, Robert Walterei. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. Journal of neurodevelopmental disorders. vol 13. issue 1. 2021-08-26. PMID:33863288. |
mtor inhibitor improves autistic-like behaviors related to tsc2 haploinsufficiency but not following developmental status epilepticus. |
2021-08-26 |
2023-08-13 |
Not clear |
| Tomas Petrasek, Iveta Vojtechova, Ondrej Klovrza, Klara Tuckova, Cestmir Vejmola, Jakub Rak, Anna Sulakova, Daniel Kaping, Nadine Bernhardt, Petrus J de Vries, Jakub Otahal, Robert Walterei. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. Journal of neurodevelopmental disorders. vol 13. issue 1. 2021-08-26. PMID:33863288. |
tuberous sclerosis complex (tsc), a multi-system genetic disorder often associated with autism spectrum disorder (asd), is caused by mutations of tsc1 or tsc2, which lead to constitutive overactivation of mammalian target of rapamycin (mtor). |
2021-08-26 |
2023-08-13 |
Not clear |
| Chen Zhu, Quan Zhou, Cong Luo, Ying Che. Dexmedetomidine Protects Against Oxygen-Glucose Deprivation-Induced Injury Through Inducing Astrocytes Autophagy via TSC2/mTOR Pathway. Neuromolecular medicine. vol 22. issue 2. 2021-07-19. PMID:31654225. |
in addition, dex enhanced the expression of tuberous sclerosis complex 2 (tsc2) in primary cultured astrocytes, while reduced the expression of mammalian target of rapamycin (mtor). |
2021-07-19 |
2023-08-13 |
Not clear |
| Camilla Russo, Anna Nastro, Domenico Cicala, Maria De Liso, Eugenio Maria Covelli, Giuseppe Cinall. Neuroimaging in tuberous sclerosis complex. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. vol 36. issue 10. 2021-06-21. PMID:32519125. |
tuberous sclerosis complex (tsc) is a rare autosomal dominant disorder affecting multiple systems, due to inactivating mutations of tsc1 or tsc2 mtor pathway genes. |
2021-06-21 |
2023-08-13 |
Not clear |
| Mouna Triki, Gianmarco Rinaldi, Melanie Planque, Dorien Broekaert, Alina M Winkelkotte, Carina R Maier, Sudha Janaki Raman, Anke Vandekeere, Joke Van Elsen, Martin F Orth, Thomas G P Grünewald, Almut Schulze, Sarah-Maria Fend. mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis. Cell reports. vol 31. issue 12. 2021-04-28. PMID:32579932. |
accordingly, activating mtor signaling by deleting tuberous sclerosis complex 2 (tsc2) or overexpression of srebp-1/2 is sufficient to increase fads2 mrna expression and sapienate metabolism in mouse embryonic fibroblasts (mefs) and u87 glioblastoma cells, respectively. |
2021-04-28 |
2023-08-13 |
mouse |
| Philip H Iffland, Allan E Barnes, Marianna Baybis, Peter B Crin. Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout. Experimental neurology. vol 334. 2021-03-10. PMID:32781001. |
tsc1 or tsc2 mutations cause tuberous sclerosis complex (tsc), and lead to mechanistic target of rapamycin (mtor) hyperactivation evidenced by hyperphosphorylation of ribosomal s6 protein and 4-elongation factor binding protein 1 (4e-bp1). |
2021-03-10 |
2023-08-13 |
Not clear |
| Philip H Iffland, Allan E Barnes, Marianna Baybis, Peter B Crin. Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout. Experimental neurology. vol 334. 2021-03-10. PMID:32781001. |
the effects of aa levels on mtor signaling and s6 and 4e-bp1 phosphorylation were analyzed in tsc2 and depdc5 (a distinct mtor regulatory gene associated with epilepsy) crispr-edited neuro2a (n2a) cells and differentiated neurons. |
2021-03-10 |
2023-08-13 |
Not clear |
| Suna Emir, Şadan Hacısalihoğlu, Derya Özyörük, Filiz Ekici, Aydan Değerliyurt, Alev Güven, İlker Çeti. Assessment of tumors in children with tuberous sclerosis: a single centre's experience. Turk pediatri arsivi. vol 52. issue 1. 2020-10-01. PMID:28439198. |
as a result of mutations in tsc1 (9q34) and tsc2 (16p13.3) tumor supressor genes, the mammalian target of the rapamycin (mtor) signaling pathway is overactivated in patients with tuberous sclerosis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Susana Boronat, Ignasi Barber, Elizabeth Anne Thiel. Sclerotic bone lesions in tuberous sclerosis complex: A genotype-phenotype study. American journal of medical genetics. Part A. vol 173. issue 7. 2020-10-01. PMID:28488386. |
tuberous sclerosis complex (tsc) is due to pathogenic variants in tsc1 or tsc2 genes resulting in hyperactivation of the mtor pathway. |
2020-10-01 |
2023-08-13 |
Not clear |
| Zixuan Zhang, Mengzhao Wan. PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. Oncology letters. vol 14. issue 2. 2020-10-01. PMID:28789352. |
in total, 4 missense mutations were found in 3 patients with tc/ac, including mutations in exon 48 of mtor (c.6667c>t), exon 21 of tuberous sclerosis complex (tsc) 1 (c.2765g>a), and exons 12 (c.1265c>t) and 19 (c.2148c>t) of tsc2. |
2020-10-01 |
2023-08-13 |
Not clear |
| Jinhyun Cho, Jeeyun Lee, Jusun Kim, Seung Tae Kim, Sujin Lee, Sun Young Kim, Sang Yun Ha, Cheol-Keun Park, Ho Yeong Li. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Translational oncology. vol 9. issue 5. 2020-09-30. PMID:27751352. |
loss of tuberous sclerosis complex 2 (tsc2) as a predictive biomarker of response to mtor inhibitor treatment in patients with hepatocellular carcinoma. |
2020-09-30 |
2023-08-13 |
Not clear |
| Jinhyun Cho, Jeeyun Lee, Jusun Kim, Seung Tae Kim, Sujin Lee, Sun Young Kim, Sang Yun Ha, Cheol-Keun Park, Ho Yeong Li. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Translational oncology. vol 9. issue 5. 2020-09-30. PMID:27751352. |
tumors with loss of tuberous sclerosis complex 2 (tsc2), a negative regulator of mtor signaling, tend to respond well to mtor inhibitors. |
2020-09-30 |
2023-08-13 |
Not clear |